Is Ginkgo Bioworks Destined to Be in a "Magnificent Seven" of Healthcare Stocks?

Could Ginkgo Bioworks Holdings (DNA -15.13%) one day be part of the healthcare sector's version of the "Magnificent Seven" group of high-performing stocks? It's more likely than you think. The Boston-based biofoundry has large aspirations to disrupt the way new drugs are developed -- and there's reason to believe that over time it could succeed in a big way. Consider the following.The argument for "magnificent" statusPerhaps the most illustrious of the current Magnificent Seven stocks (which all focus on te ...